{
  "id" : "aOyvQqfF",
  "url" : "https://kurier.at/wirtschaft/impfstoff-entwickler-sk-vor-milliardenschwerem-boersengang/401210929",
  "category" : "ECONOMICS",
  "publisher" : "kurier.at",
  "publishedOn" : "2021-03-08T08:00:26Z[UTC]",
  "author" : "von Manfred Seeh von Oliver Pink von Christine Imlinger",
  "imageUrl" : "https://image.kurier.at/images/original/4948207/20210218-ABD0168-1-1.jpg",
  "imageCopyright" : "APA - Austria Presse Agentur",
  "sourceCountry" : "austria",
  "sourceLanguage" : "german",
  "targetLanguage" : "english",
  "articleTitle" : "Impfstoff-Entwickler SK Bioscience vor milliardenschwerem Börsengang",
  "articleTitleTranslated" : "Vaccine developer SK Bioscience ahead of a billion-dollar IPO",
  "articleContent" : [ "Die südkoreanische Pharmafirma SK Bioscience nimmt beim geplanten Börsengang umgerechnet rund 1,1 Milliarden Euro ein. Der Impfstoff-Entwickler teilt seine Aktien zu je 65.000 Won (48,25 Euro) und damit am oberen Ende der Angebotsspanne zu.", "Das Unternehmen produziert den Corona-Impfstoff von AstraZeneca und entwickelt ein eigenes Vakzin gegen die Pandemie." ],
  "articleContentTranslated" : [ "The South Korean pharmaceutical company SK Bioscience will earn around 1.1 billion euros from the planned IPO. The vaccine developer is allocating its shares at 65,000 won (48.25 euros) each, which is at the upper end of the offering range.", "The company produces AstraZeneca's corona vaccine and is developing its own vaccine against the pandemic." ]
}